Ondansetron Orally Disintegrating Tablets
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-R-0018
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued a solicitation (Procurement Identifier: SPE2D2-25-R-0018) for the supply of Ondansetron Orally Disintegrating Tablets (ODT). This procurement is classified under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further identified by Product Service Code 6505, indicating a focus on pharmaceutical products.
The primary objective of this solicitation is to secure a reliable source of Ondansetron ODT, a medication commonly used to prevent nausea and vomiting caused by various medical treatments. The intended outcome is to ensure the consistent availability of this critical pharmaceutical product to support the health and readiness of military personnel and other beneficiaries served by the DLA.
This procurement is being conducted in accordance with the procedures outlined in 41 U.S.C. 1901, as implemented by Class Deviation 2026-O0028. It leverages the Revolutionary Federal Acquisition Regulation (FAR) Overhaul Part 12, the Defense FAR Supplement (DFARS) Part 212, and the updated FAR Overhaul Part 12.201-1. These regulatory frameworks are designed to streamline the acquisition process and promote efficiency in federal procurement activities. Amendment 0004 has been issued to reflect these procedural updates, and interested parties are advised to review the revised solicitation documents attached to the notice.
Key requirements for this solicitation include the manufacturing and timely delivery of Ondansetron Orally Disintegrating Tablets in accordance with all applicable federal standards and specifications. Offerors are expected to demonstrate their capability to meet quality, safety, and regulatory compliance requirements throughout the contract period. The solicitation may include additional technical, packaging, and delivery specifications, which are detailed in the attached documents available through the provided SAM.gov link.
The contracting entity for this opportunity is DLA Troop Support, a federal office within the Defense Logistics Agency. The primary point of contact for this solicitation is Nancy Fernandez, who can be reached at [email protected] or 445-737-0713. A secondary contact, Jason C. Wray, is also available at [email protected] or 445-737-6304. These contacts can provide further clarification regarding solicitation requirements and submission procedures.
The notice was posted on August 4, 2026, with a response deadline of April 22, 2026, at 19:04. The solicitation is currently active, and all interested contractors are encouraged to review the full solicitation and its six attachments via the official SAM.gov opportunity page (https://sam.gov/opp/5bdd0ce9e9f34d9f911b37c1f9e94bc0/view).
Contractors considering this opportunity should ensure their capabilities align with the pharmaceutical manufacturing requirements specified under NAICS 325412 and be prepared to comply with all federal acquisition regulations and DLA-specific standards. No set-aside requirements or special considerations have been specified in the provided information. This procurement represents a significant opportunity for qualified manufacturers to support the Department of Defense’s pharmaceutical supply chain with a critical medication.
Documents6